Vantictumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vantictumab
Monoclonal antibody
Type ?
Source Human
Target Frizzled receptor
Clinical data
Routes of
administration
IV
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6322H9722N1674O1988S46
Molar mass 142.5 kg/mol

Vantictumab /vænˈtɪktᵿmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vanticitumab.[4]

It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]

Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer.[5]

References[edit]